BioPartner UK leads the UK Delegation to several partnering conferences each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.
BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.
Our breakthrough technology combines synthetic and stem cell biology, offering limitless possibilities. Enabling a new generation of cell therapies, providing the best human cells for research and drug discovery, and allowing the control of advanced synthetic biology circuits for biomanufacturing.
Cello Health is organised around three core capabilities - Insight, Consulting and Communications - which allows us to look at complex market challenges through ‘multiple lenses’. This enables us to help healthcare businesses unlock the potential of their assets, brands and organisations in a changing and challenging environment. The formation of Cello Health reflects industry pressure to optimise the potential of molecular assets and demonstrate value, recognises the loss of blockbusters, and the subsequent impact on available resources to bring brands to market. The Cello Health structure gives us a broader view of commercial and clinical success and enables us to provide a greater depth and breadth of services to help support your critical decision making.
Curileum Discovery Ltd is a new regenerative medicine company in London focused on identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues. Effective tissue regeneration requires activation of endogenous healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal.
We are applying three decades of stem cell drug discovery and development experience to unlock a whole new range of therapeutic targets to kill defective stem cells and to activate healthy stem cells to restore health to the intestine.
Domainex is a drug discovery service company based in Cambridge UK providing protein expression, assay development and screening, hit generation (fragment/virtual screening), and integrated medicinal chemistry incorporating in vitro pharmacology, in vivo DMPK, computational design and synthetic/analytical chemistry.
ERA Consulting (UK)
ERA is able to contribute at any stage of product development, from discovery, through process development, non-clinical and clinical aspects, to regulatory approval and beyond. One of our recognised specialities is the design of a regulatory strategy, to cover part or all of the development process. Thus, our services include the following: Regulatory due diligence exercises for in- or out-licensing, interactions with regulatory agencies, such as pre-IND, pre-BLA and scientific advice procedures, clinical trial applications, marketing authorisation applications, including eCTD submissions, post-approval amendments or variations, advice on process development, including validation, input on characterisation and control, consulting on non-clinical and clinical strategy, facility inspections and support for establishment licensing.
Eurofins Selcia Drug Discovery
Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling. In January 2018 Selcia became part of Eurofins Pharma Discovery Services affording Selcia the capacity to deliver extensive and seamless solutions and services that span the whole spectrum of drug discovery.
Selcia Drug Discovery focusses on integrated small molecule drug discovery, with a strong track record of IP generation and preclinical candidate delivery for customers – 25 patents and 11 preclinical candidates generated. USPs are the medicinal chemistry of macrocycles, and a peptidyl prolyl isomerase (PPIase) screening platform.
Selcia radiolabelling specialises in 14C GMP radiolabelling, producing 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, IV microdosing, dermal penetration, regulatory and environmental fate studies.
Selcia also offers GLP NMR and mass spectrometry services to support regulatory submissions, and specialised purification capabilities from analytical (µg) to multi-100g scale.
Areas of Expertise:
• Medicinal chemistry: Tool compounds; peptides; macrocycles; natural product chemistry
• Biology: Assay development; ADME screens; PPIase profiling
• Disease expertise: Anti-infectives; inflammation; CNS; pain; metabolic; oncology & ophthalmology
• Target classes: GPCRs; ion channels; enzymes; protein-protein interactions
• 14C Custom Radiosynthesis
• GMP 14C Radiolabelled API for Clinical Trials
• GLP/GMP Analytics – GLP NMR
• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds
Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion provides contract services include...
- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services
Strategic pharmaceutical and pre-clinical consulting services. Critical due diligence, rationalisation and evaluation of IP portfolios, academic research and early-stage/preclinical projects - ultimately looking to de-risk and increase commercial attractiveness and licensing potential.
Advising and supporting academic institutions and start-up companies on out-sourcing strategies - looking for cost-effective solutions and accelerating the speed of progression and completion of projects.
Oversight and management of outsourced CMC and preclinical projects.
Undertaking due diligences on behalf of organisations in- and out-licencing development drug candidates.
Exploring innovative business models and opportunities for funding between academia and the out-sourcing network, looking to create collaborative win-win partnerships to progress projects.
Attending conferences and exhibitions on behalf of clients, evaluating new product opportunities and service providers.